LPL Financial LLC Boosts Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

LPL Financial LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 207,003 shares of the biopharmaceutical company's stock after purchasing an additional 55,410 shares during the period. LPL Financial LLC owned approximately 0.16% of Halozyme Therapeutics worth $9,897,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth approximately $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its position in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth $69,000. Finally, Parkside Financial Bank & Trust grew its position in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares during the period. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $3.11 during trading on Wednesday, hitting $60.65. 2,068,251 shares of the stock traded hands, compared to its average volume of 1,404,554. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The company has a fifty day moving average price of $60.12 and a two-hundred day moving average price of $54.89. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $66.00. The company has a market cap of $7.49 billion, a price-to-earnings ratio of 17.68, a P/E/G ratio of 0.42 and a beta of 1.32.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the sale, the director now directly owns 33,108 shares in the company, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,200 shares of company stock valued at $1,286,568. 2.40% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on HALO shares. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Benchmark reissued a "buy" rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.